Potential use of custirsen to treat prostate cancer

References

• American Cancer SocietyCancer Facts and Figures2012Atlanta, GAAmerican Cancer Society2012
   Google Scholar
• SiegelRDeSantisCVirgoKCancer treatment and survivorship statistics, 2012CA Cancer J Clin201262422024122700443
   PubMed Web of Science ®Google Scholar
  CA Cancer J Clin201262348
   Google Scholar
• TannockIFde WitRBerryWRDocetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancerN Engl J Med20043511502151215470213
   PubMed Web of Science ®Google Scholar
• PetrylakDPTangenCMHussainMHDocetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancerN Engl J Med20043511513152015470214
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer NetworkClinical Practice Guidelines in Oncology (NCCN Guideline®). Prostate Cancer Version 3Fort Washington, PANational Comprehensive Cancer Network2012
   Google Scholar
• MachielsJPMazzeoFClausseMProspective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancerJ Clin Oncol2008265261526818794543
   PubMed Web of Science ®Google Scholar
• SmallEDemkowTGerritsenWRA Phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC)Abstract 7 presented at the American Society of Clinical Oncology Genitourinary Cancers SymposiumFebruary 26–28, 2009Orlando, FL
   Google Scholar
• KellyWKHalabiSCarducciMRandomized, double-blind, placebo-controlled Phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401J Clin Oncol2012301534154022454414
   PubMed Web of Science ®Google Scholar
• TannockIFizaziKIvanovSAflibercept versus placebo in combination with docetaxel/prednisone for first-line treatment of men with metastatic castration-resistant prostate cancer (mCRPC): results from the multinational Phase III trial (VENICE)J Clin Oncol201331Suppl 6Abstr 13
   Web of Science ®Google Scholar
• PetrylakDPFizaziKSternbergCA Phase 3 study to evaluate the efficacy and safety of docetaxel and prednisone (DP) with or without lenalidomide (LEN) in patients with castrate-resistant prostate cancer (CRPC): the MAINSAIL TrialAbstract LBA24 presented at the European Society for Molecular Oncology CongressJune 6–9, 2012Berlin, Germany
   Google Scholar
• ArmstrongAJCreelPTurnbullJA Phase I–II study of docetaxel and atrasentan in men with castration-resistant metastatic prostate cancerClin Cancer Res2008146270627618829508
   PubMed Web of Science ®Google Scholar
• FizaziKHiganoCNelsonJPhase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan (ZD4054) in patients with metastatic castration-resistant prostate cancerJ Clin Oncol2013311740174723569308
   PubMed Web of Science ®Google Scholar
• ScherHIJiaXChiKRandomized, open-label Phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancerJ Clin Oncol2011292191219821483004
   PubMed Web of Science ®Google Scholar
• AraujoJCTrudelGCSaadFOverall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): results from the randomized Phase III READY trialJ Clin Oncol201231Suppl 6Abstr LBA8
   Google Scholar
• KantoffPWHiganoCSShoreNDSipuleucel-T immunotherapy for castration-resistant prostate cancerN Engl J Med201036341142220818862
   PubMed Web of Science ®Google Scholar
• de BonoJSOudardSOzgurogluMPrednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialLancet20103761147115420888992
   PubMed Web of Science ®Google Scholar
• de BonoJSLogothetisCJMolinaAAbiraterone and increased survival in metastatic prostate cancerN Engl J Med20113641995200521612468
   PubMed Web of Science ®Google Scholar
• NilssonSFranzénLParkerCTwo-year survival follow-up of the randomized, double-blind, placebo-controlled Phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastasesClin Genitourin Cancer201311202623021204
   PubMed Web of Science ®Google Scholar
• ScherIHFizaziKSaadFIncreased survival with enzalutamide in prostate cancer after chemotherapyN Engl J Med20123671187119722894553
   PubMed Web of Science ®Google Scholar
• GaestelMMolecular chaperones in signal transductionHandb Exp Pharmacol20061729310916610356
   PubMedGoogle Scholar
• VabulasRMRaychaudhuriSHayer-HartlMHartlFUProtein folding in the cytoplasm and the heat shock responseCold Spring Harb Perspect Biol20102a00439021123396
   PubMed Web of Science ®Google Scholar
• RocchiPSoAKojimaSHeat shock protein 27 increases after androgen ablation and plays a cytoprotective role in hormone-refractory prostate cancerCancer Res2004646595660215374973
   PubMed Web of Science ®Google Scholar
• ZoubeidiAChiKGleaveMTargeting the cytoprotective chaperone, clusterin, for treatment of advanced cancerClin Cancer Res2010161088109320145158
   PubMed Web of Science ®Google Scholar
• JonesSEJomaryCClusterinInt J Biochem Cell Biol20023442743111906815
   PubMed Web of Science ®Google Scholar
• LiHLiuSZhuXYangSXiangJChenHClusterin immunoexpression and its clinical significance in patients with non-small cell lung cancerLung201018842343120614220
   PubMed Web of Science ®Google Scholar
• MiyakeHGleaveMKamidonoSHaraIOverexpression of clusterin in transitional cell carcinoma of the bladder is related to disease progression and recurrenceUrology20025915015411796313
   PubMed Web of Science ®Google Scholar
• RosenbergMESilkensenJClusterin: physiologic and pathophysiologic considerationsInt J Biochem Cell Biol1995276336457648419
   PubMed Web of Science ®Google Scholar
• YuJTTanLThe role of clusterin in Alzheimer’s disease: pathways, pathogenesis, and therapyMol Neurobiol20124531432622274961
   PubMed Web of Science ®Google Scholar
• NizardPTetleySLe DréanYStress-induced retrotranslocation of clusterin/ApoJ into the cytosolTraffic2007855456517451556
   PubMed Web of Science ®Google Scholar
• HumphreysDTCarverJAEasterbrook-SmithSBWilsonMRClusterin has chaperone-like activity similar to that of small heat shock proteinsJ Biol Chem19992746875688110066740
   PubMed Web of Science ®Google Scholar
• KumitaJRPoonSCaddyGLThe extracellular chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with prefibrillar speciesJ Mol Biol200736915716717407782
   PubMed Web of Science ®Google Scholar
• WyattARYerburyJJBerghoferPClusterin facilitates in vivo clearance of extracellular misfolded proteinsCell Mol Life Sci2011683919393121505792
   PubMed Web of Science ®Google Scholar
• ZhangQZhouWKunduSThe leader sequence triggers and enhances several functions of clusterin and is instrumental in the progression of human prostate cancer in vivo and in vitroBJU Int20069845246016879694
   PubMed Web of Science ®Google Scholar
• ZhangHKimJKEdwardsCAClusterin inhibits apoptosis by interacting with activated BaxNat Cell Biol2005790991516113678
   PubMed Web of Science ®Google Scholar
• ZoubeidiAEttingerSBeraldiEClusterin facilitates COMMD1 and I-kappa B degradation to enhance NF-kappa B activity in prostate cancer cellsMol Cancer Res2010811913020068069
   PubMed Web of Science ®Google Scholar
• ShiotaMZardanATakeuchiAClusterin mediates TGF-β-induced epithelial-mesenchymal transition and metastasis via Twist 1 in prostate cancer cellsCancer Res2012725261527222896337
   PubMed Web of Science ®Google Scholar
• KevansDFoleyJTenniswoodMHigh clusterin expression correlates with a poor outcome in stage II colorectal cancersCancer Epidemiol Biomarkers Prev20091839339919155441
   PubMed Web of Science ®Google Scholar
• KurahashiTMuramakiMYamanakaKHaraIMiyakeHExpression of the secreted form of clusterin protein in renal cell carcinoma as a predictor of disease extensionBJU Int20059689589916153225
   PubMed Web of Science ®Google Scholar
• RedondoMVillarETorres-MuñozJTellezTMorellMPetitoCKOverexpression of clusterin in human breast carcinomaAm J Pathol200015739339910934144
   PubMed Web of Science ®Google Scholar
• SteinbergJOyasuRLangSIntracellular levels of SGP-2 (clusterin) correlate with tumor grade in prostate cancerClin Cancer Res19973170717119815554
   PubMed Web of Science ®Google Scholar
• XieDLauSHShamJSUpregulated expression of cytoplasmic clusterin in human ovarian carcinomaCancer200510327728315578711
   PubMed Web of Science ®Google Scholar
• CochraneDRWangZMuramakiMGleaveMENelsonCCDifferential regulation of clusterin and its isoforms by androgens in prostate cellsJ Biol Chem20072822278228717148459
   PubMed Web of Science ®Google Scholar
• JulyLVAkbariMZellwegerTJonesECGoldenbergSLGleaveMEClusterin expression is significantly enhanced in prostate cancer cells following androgen withdrawal therapyProstate20025017918811813210
   PubMed Web of Science ®Google Scholar
• PattersonSGWeiSChenXNovel role of Stat1 in the development of docetaxel resistance in prostate tumor cellsOncogene2006256113612216652143
   PubMed Web of Science ®Google Scholar
• SoweryRDHadaschikBASoAIClusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapyBJU Int200810238939718336596
   PubMed Web of Science ®Google Scholar
• MiyakeHNelsonCRenniePSGleaveMETestosterone-repressed prostate message-2 is an antiapoptotic gene involved in progression to androgen independence in prostate cancerCancer Res20006017017610646870
   PubMed Web of Science ®Google Scholar
• MiyakeHNelsonCRenniePSGleaveMEAcquisition of chemoresistant phenotype by overexpression of the antiapoptotic gene testosterone-repressed prostate message-2 in prostate cancer xenograft modelsCancer Res2000602547255410811138
   PubMed Web of Science ®Google Scholar
• ZellwegerTKiyamaSChiKOverexpression of the cytoprotective protein clusterin decreases radiosensitivity in the human LNCaP prostate tumour modelBJU Int20039246346912930442
   PubMed Web of Science ®Google Scholar
• GleaveMEMoniaBPAntisense therapy for cancerNat Rev Cancer2005546847915905854
   PubMed Web of Science ®Google Scholar
• BedikianAYMillwardMPehambergerHBcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study GroupJ Clin Oncol2006244738474516966688
   PubMed Web of Science ®Google Scholar
• Chanan-KhanAANiesvizkyRHohlRJPhase III randomised study of dexamethasone with or without oblimersen sodium for patients with advanced multiple myelomaLeuk Lymphoma20095055956519373653
   PubMed Web of Science ®Google Scholar
• ISIS Pharmaceuticals Available from: http://ir.isispharm.com/phoenix.zhtml?c=222170&p=irol-newsArticle_pf&ID=1290234&highlightAccessed January 8, 2013
   Google Scholar
• ZellwegerTMiyakeHCooperSAntitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2′-O-(2-methoxy)ethyl chemistryJ Pharmacol Exp Ther200129893494011504787
   PubMed Web of Science ®Google Scholar
• MoniaBPLesnikEAGonzalezCEvaluation of 2′-modified oligonucleotides containing 2′-deoxy gaps as antisense inhibitors of gene expressionJ Biol Chem199326814514145228390996
   PubMed Web of Science ®Google Scholar
• HenrySSteckerKBrooksDMonteithDConklinBBennettCFChemically modified oligonucleotides exhibit decreased immune stimulation in miceJ Pharmacol Exp Ther200029246847910640282
   PubMed Web of Science ®Google Scholar
• ChiKNHotteSJEllardSA randomized Phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC)J Clin Oncol201230SupplAbstr 4514
   Google Scholar
• ChiKNHotteSJEllardSA randomized Phase II study of OGX-427 plus prednisone versus prednisone alone in patients with chemotherapy-naive metastatic castration-resistant prostate cancerJ Clin Oncol201230Suppl 5Abstr 121
   Web of Science ®Google Scholar
• SoAIBlackPCChiKNA Phase I trial of intravesical antisense oligonucleotide targeting heat shock protein 27 (OGX-427) for the treatment of non-muscle-invasive bladder cancerJ Clin Oncol201230Suppl 5Abstr 286
   Web of Science ®Google Scholar
• TalbotDCRansonMDaviesJTumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose studyClin Cancer Res2010166150615821041181
   PubMed Web of Science ®Google Scholar
• CaoCShinoharaETLiHClusterin as a therapeutic target for radiation sensitization in a lung cancer modelInt J Radiat Oncol Biol Phys2005631228123616253777
   PubMed Web of Science ®Google Scholar
• SoASinnemannSHuntsmanDFazliLGleaveMKnockdown of the cytoprotective chaperone, clusterin, chemosensitizes human breast cancer cells both in vitro and in vivoMol Cancer Ther200541837184916373699
   PubMed Web of Science ®Google Scholar
• GleaveMMiyakeHUse of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancerWorld J Urol200523384615770517
   PubMed Web of Science ®Google Scholar
• JulyLVBeraldiESoANucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivoMol Cancer Ther2004322323215026542
   PubMed Web of Science ®Google Scholar
• MuramakiMSoAHayashiNChemosensitization of gemcitabine-resistant human bladder cancer cell line both in vitro and in vivo using antisense oligonucleotide targeting the anti-apoptotic gene, clusterinBJU Int200910338439019007378
   PubMed Web of Science ®Google Scholar
• ChiKNEisenhauerEFazliLA Phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2′-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancerJ Natl Cancer Inst2005971287129616145049
   PubMed Web of Science ®Google Scholar
• ChiKNGoldenbergLKollmannsbergerCMurrayNFazliLGleaveMEA Phase II neoadjuvant study of OGX-011, a 2′methoxyethyl phosphorothioate antisense to clusterin, in patients with prostate cancer prior to prostatectomyAbstract 167 presented at the American Society of Clinical Oncology Genitourinary Cancers SymposiumFebruary 14–16, 2008San Francisco, CA
   Google Scholar
• ChiKNHotteSJYuEYRandomized Phase II study of docetaxel and prednisone with or without OGX-011 in patients with metastatic castration-resistant prostate cancerJ Clin Oncol2010284247425420733135
   PubMed Web of Science ®Google Scholar
• SaadFHotteSNorthSRandomized Phase II trial of custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG Trial P-06Clin Cancer Res2011175765577321788353
   PubMed Web of Science ®Google Scholar
• ChiKNSiuLLHirteHA Phase I study of OGX-011, a 2′-methoxyethyl phosphorothioate antisense to clusterin, in combination with docetaxel in patients with advanced cancerClin Cancer Res20081483383918245546
   PubMed Web of Science ®Google Scholar
• BertholdDRPondGRdeWit REisenbergerMTannockifTAX 327 InvestigatorsSurvival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versaAnn Oncol2008191749175318487550
   PubMed Web of Science ®Google Scholar
• JankovicBBeardsleyEChiKNRechallenge with docetaxel as second-line chemotherapy in patients with metastatic hormone refractory prostate cancer (HRPC) after previous docetaxel: a population based analysisAbstract 196 presented at the American Society of Clinical Oncology Genitourinary Cancers SymposiumFebruary 14–16, 2008San Francisco, CA
   Google Scholar
• NemunaitisJHolmlundJTKraynakMPhase I evaluation of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C-alpha, in patients with advanced cancerJ Clin Oncol1999173586359510550158
   PubMed Web of Science ®Google Scholar
• WatersJSWebbACunninghamDPhase I clinical and pharmacokinetic study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin’s lymphomaJ Clin Oncol2000181812182310784621
   PubMed Web of Science ®Google Scholar
• ChiKNDe BonoJSHiganoCSSYNERGY: a randomized Phase III study comparing first-line docetaxel/prednisone to docetaxel/prednisone plus custirsen in metastatic castrate-resistant prostate cancer (mCRPC)J Clin Oncol2011SupplAbstr TPS180
   Web of Science ®Google Scholar